OGEN Valuation
Oragenics Inc
$
1.030
- Overview
- Forecast
- Valuation
- Earnings
OGEN Relative Valuation
OGEN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OGEN is overvalued; if below, it's undervalued.
Historical Valuation
Oragenics Inc (OGEN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.41. The fair price of Oragenics Inc (OGEN) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：1.03
Fair
-1.47
PE
1Y
3Y
5Y
Trailing
Forward
-0.42
EV/EBITDA
Oragenics Inc. (OGEN) has a current EV/EBITDA of -0.42. The 5-year average EV/EBITDA is -0.01. The thresholds are as follows: Strongly Undervalued below -0.10, Undervalued between -0.10 and -0.05, Fairly Valued between 0.04 and -0.05, Overvalued between 0.04 and 0.09, and Strongly Overvalued above 0.09. The current Forward EV/EBITDA of -0.42 falls within the Strongly Undervalued range.
-0.42
EV/EBIT
Oragenics Inc. (OGEN) has a current EV/EBIT of -0.42. The 5-year average EV/EBIT is -0.86. The thresholds are as follows: Strongly Undervalued below -3.54, Undervalued between -3.54 and -2.20, Fairly Valued between 0.47 and -2.20, Overvalued between 0.47 and 1.81, and Strongly Overvalued above 1.81. The current Forward EV/EBIT of -0.42 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Oragenics Inc. (OGEN) has a current PS of 0.00. The 5-year average PS is 23.90. The thresholds are as follows: Strongly Undervalued below -186.18, Undervalued between -186.18 and -81.14, Fairly Valued between 128.94 and -81.14, Overvalued between 128.94 and 233.98, and Strongly Overvalued above 233.98. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Oragenics Inc. (OGEN) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.36. The thresholds are as follows: Strongly Undervalued below -4.91, Undervalued between -4.91 and -3.13, Fairly Valued between 0.42 and -3.13, Overvalued between 0.42 and 2.20, and Strongly Overvalued above 2.20. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.13
P/FCF
Oragenics Inc. (OGEN) has a current P/FCF of 0.13. The 5-year average P/FCF is 0.12. The thresholds are as follows: Strongly Undervalued below -4.24, Undervalued between -4.24 and -2.06, Fairly Valued between 2.30 and -2.06, Overvalued between 2.30 and 4.48, and Strongly Overvalued above 4.48. The current Forward P/FCF of 0.13 falls within the Historic Trend Line -Fairly Valued range.
Oragenics Inc (OGEN) has a current Price-to-Book (P/B) ratio of -0.40. Compared to its 3-year average P/B ratio of 0.89 , the current P/B ratio is approximately -144.73% higher. Relative to its 5-year average P/B ratio of 2.70, the current P/B ratio is about -114.73% higher. Oragenics Inc (OGEN) has a Forward Free Cash Flow (FCF) yield of approximately -160.64%. Compared to its 3-year average FCF yield of -160.82%, the current FCF yield is approximately -0.11% lower. Relative to its 5-year average FCF yield of -107.66% , the current FCF yield is about 49.22% lower.
-0.43
P/B
Median3y
0.89
Median5y
2.70
-163.33
FCF Yield
Median3y
-160.82
Median5y
-107.66
Competitors Valuation Multiple
The average P/S ratio for OGEN's competitors is 0.38, providing a benchmark for relative valuation. Oragenics Inc Corp (OGEN) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of OGEN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of OGEN in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Oragenics Inc (OGEN) currently overvalued or undervalued?
Oragenics Inc (OGEN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.41. The fair price of Oragenics Inc (OGEN) is between to according to relative valuation methord.
What is Oragenics Inc (OGEN) fair value?
How does OGEN's valuation metrics compare to the industry average?
What is the current P/B ratio for Oragenics Inc (OGEN) as of Aug 30 2025?
What is the current FCF Yield for Oragenics Inc (OGEN) as of Aug 30 2025?
What is the current Forward P/E ratio for Oragenics Inc (OGEN) as of Aug 30 2025?